Colon cancer angiogenesis and antiangiogenic therapy

Bibliography

• FOLKMAN J: How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res. (1986) 46:467–473.
   Google Scholar
• •Review highlighting initial work in the field of cancer angiogenesis.
   Google Scholar
• ELLIS LM: Tumor angiogenesis. In: Surgical Research. WW Souba, DW Wilmore (Eds), Acadenic Press, San Francisco, CA, USA (2000):350–355.
   Google Scholar
• ••Comprehensive review detailing multiplemediators of tumour angiogenesis.
   Google Scholar
• FOLKMAN J: What is the evidence that tumors are angiogenesis dependent? Natl. Cancer Inst (1989) 82:4–6.
   Google Scholar
• ••Review of data demonstrating theimportance of angiogenesis and tumour growth and metastatic potential.
   Google Scholar
• BOUCK N: Tumor angiogenesis: the role of oncogenes and tumor suppressor genes. Cancer Cells. (1990) 2:179–185.
   PubMed Web of Science ®Google Scholar
• FIDLER IJ, ELLIS LM: The implications of angiogenesis to the biology and therapy of cancer metastasis. Cell (1994) 79:185–188.
   PubMed Web of Science ®Google Scholar
• •Briefly describes preliminary evidence of antiangiogenic therapy.
   Google Scholar
• FOLKMAN J, TYLER K: Tumor angiogenesis: its possible role in metasasis and invasion. In: Cancer Invasion, and Metastasis: Biologic Mechanisms and Therapy SB Day, WPL Myers, P Stansly, S Gerattini, MG Lewis (Eds), Raven Press, New York, USA (1977):5–103.
   Google Scholar
• ••Hallmark review of the novel concept oftumour, metastatic potential and angiogenesis.
   Google Scholar
• KECK PJ, HAUSER SD, KRIVI G et al: Vascular permeability factor, an endothelial cell mitogen related to PDGE Science (1989) 246:1309–1312.
   Google Scholar
• •Paper describes the structure and function of VEGE
   Google Scholar
• TISCHER E, MITCHELL R, HARTMAN T et al.: The human gene for vascular endothelial cell growth factor. Multiple protein forms are encoded through alternate exon splicing. Biol. Chem. (1991) 266:11947–11954.
   Google Scholar
• TAKAHASHI Y, KITADAI Y, BUCANA CD et al.: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. (1995) 55:3964–3968.
   PubMed Web of Science ®Google Scholar
• O'BYRNE KJ, KOUKOURAKIS MI, GIATROMANOLAKI A et al.: Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small cell lung cancer. Br. J. Cancer (2000) 82:3964–3968.
   Google Scholar
• MAEDA K, CHUNG YS, OGAWA Y et al.: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer (1996) 77:858–863.
   PubMed Web of Science ®Google Scholar
• JACOBSEN J, RASMUSON T, GRANKVIST K et al.: Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J. Urol. (2000) 163:343–347.
   PubMed Web of Science ®Google Scholar
• LINDERHOLM B, GRANKVIST K, WILKING N et al.: Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J. Gin Oncol. (2000) 18:1423–1431.
   Web of Science ®Google Scholar
• AHMAD SA, SHAHEEN RM, LIU W et al.: Regulators of colon cancer angiogenesis. Emerg. The]: Target. (2000) 4:1–12.
   Google Scholar
• ZEBROWSKI BK, YANO S, LIU W et al.:Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusion. Gin. Cancer Res. (1999) 5:3364–3368.
   Web of Science ®Google Scholar
• KANNO S, ODA N, ABE M et al.: Rolesof two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene (2000) 19:2138–2146.
   PubMed Web of Science ®Google Scholar
• BRUNS CJ, LIU W, DAVIS DW et al.: Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastasis. Cancer (2000) 89:488–499.
   PubMed Web of Science ®Google Scholar
• WONG MP, CHEUNG N, YUEN ST, LEUNG SY, CHUNG LP: Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumor progression. hat. J. Cancer (1999) 81:845–850.
   PubMed Web of Science ®Google Scholar
• TAKAHASI Y, KITADAI Y, BUCANA CD, CLEARY KR, ELLIS LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res. (1995) 55:3964–3968.
   PubMed Web of Science ®Google Scholar
• ••Important paper that describes thecorrelation of VEGF expression and metastatic potential of human colon cancer.
   Google Scholar
• TAKAHASHI Y, TUCKER SI, KITADAI Y et al.: Vessel counts and expression of vaqscular endothelial growth factor as a prognostic factor in node negative colon cancer. Arch. Surg. (1997) 132:541–546.
   PubMed Web of Science ®Google Scholar
• SHIRAISHI A, ISHIWATA T, SHOJI T,ASANO G: Expression of PCNA, basic fibroblast growth factor, FGF-receptor and vascular endothelial growth factor in adenomas and carcinomas of human colon cancer. Acta Histochem. Cytochem. (1995) 28:21–29.
   Web of Science ®Google Scholar
• LEE J, CHOW N, WANG S, HUANG S: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Ear: J. Cancer (2000) 36:748–753.
   PubMed Web of Science ®Google Scholar
• •Demonstrates VEGF expression in colorectal cancer specimens.
   Google Scholar
• AMAYA H, TANIGAWA N, LU C et al: Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/ platelet-derived endothelial cell growth 639 Expert Op/n. Investig. Drugs (2004) 13(6) factor expression in human colorectal cancer. Cancer Lett. (1997) 119:227–235.
   Google Scholar
• MATSURA T, KURATATE I, TERAMACHI K, OSAKI M, FUKUDA Y, ITO H: Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas. Cancer Res. (1999) 59:5037–5040.
   PubMed Web of Science ®Google Scholar
• MIYADERA K, SUMIZAWA T, HARAGUCHI MN et al: Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res. (1995) 55:1687–1690.
   PubMed Web of Science ®Google Scholar
• BAEZINGER NL, BRODIE GN, MAJERUS PW: Isolation and properties of a thrombin-sensitive protein of human platelets. Biol. Chem. (1972) 247:2723–2731.
   Web of Science ®Google Scholar
• TOKUNAGA T, NAKAMURA M, OSHIKA Y et al.: Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br: J. Cancer (1999) 79:354–359.
   Google Scholar
• TOKUNAGA T, NAKAMURA M, OSHIKA Y et al.: Alterations in tumor supressor gene p53 correlate with inhibition of thrombospondin-1 gene expression in colon cancer cells. Virchows Arch. (1998) 433:415–418.
   PubMed Web of Science ®Google Scholar
• TSUCHIDA T, KIJIMA H, TOKUNAGA T et al.: Expression of the thrombospondin-1 receptor CD36 is correlated with decreased stromal vascularisation in colon cancer. Int. Oncol (1999) 14:47–51.
   PubMed Web of Science ®Google Scholar
• PETERS KG: Vascular endothelial growthfactor and the angiopoietins: working together to build a better blood vessel. Circ. Res. (1998) 83:342–343.
   PubMed Web of Science ®Google Scholar
• MAISONPIERRE PC, SURI C, JONES PF et al.: Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science (1997) 277:55–60.
   PubMed Web of Science ®Google Scholar
• SURI C, MCCLAIN J, THURSTON G et al.: Angiopoietin-1 promotes increased vascularisation in vivo. Science (1998) 282:468–471.
   PubMed Web of Science ®Google Scholar
• DUMONT DJ, GRADWOHL G, FONG GH et al.: Dominant negative and targeted null mutations in the endothelial cell receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. (1994) 8:1897–1909.
   PubMed Web of Science ®Google Scholar
• ASHARA T, CHEN D, TAKAHASHI T et al.: Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2 modulate VEGF-induced postnatal neovascularization. Circ. Res. (1998) 83:233–240.
   PubMed Web of Science ®Google Scholar
• STRATMAN A, RISAU W, PLATE KH: Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am. Pathol (1998) 153:1459–1466.
   PubMed Web of Science ®Google Scholar
• AHMAD SA, WENBIAO L, JUNG YD et al.: Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma: a possible mechanism for the initiation of angiogenesis. Cancer (2001) 92:1138–1143.
   PubMed Web of Science ®Google Scholar
• AHMAD SA, WENBIAO L, YOUNG D et al.: The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res. (2001) 61:1255–1259.
   PubMed Web of Science ®Google Scholar
• IVASKA J, HEINO J: Adhesion receptors and cell invasion: mechanisms of integrin-guided degradation of extracellular matrix. Cell Ma. Life Sci. (2000) 57:16–24.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER M, BROOKS PC, SHAFFER RW et al.: Definition of two angiogenic pathways by distinct av intregrins. Science (1995) 270:1500–1502.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, CLARK RA, CHERESH DA: Requirement of vascular intregrin avB3 for angiogenesis. Science (1994) 264:569–571.
   PubMed Web of Science ®Google Scholar
• REINMUTH N, LIU W, AHMAD SA et al.: a,B3Integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. (2003) 63:2079–2087.
   PubMed Web of Science ®Google Scholar
• WARREN RS, YUAN H, MALTI MR, GILLETT NA, FERRARA N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. Clin. Invest. (1995) 95:1789–1797.
   Google Scholar
• SHAHEEN PM, AHMAD SA, LIU W et al.: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br. J. Cancer (2001) 85:584–589.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, CAPUTO R, DAMIANO V et al.: Antitumor effects of ZD6474, a small molecule VEGFR tyrosine kinase inhibitor, with additional activity against EGF receptor tyrosine kinase. Clin. Cancer Res. (2003) 9:1546–1556.
   PubMed Web of Science ®Google Scholar
• MANLEY PW, MARTINY-BARON G, SCHLAEPPI JM, WOOD JM: Therapies directed at vascular endothelial growth factor. Expert Opin. Investig. Drugs (2002) 11:1715–1736.
   PubMed Web of Science ®Google Scholar
• FONG TA, SHAWVER LK, SUN L et al.: 5U5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. (1999) 59:99–106.
   PubMed Web of Science ®Google Scholar
• SUN L, TRAN N, LIANG C et al.: Design, synthesis and evaluations of substituted 3- [(3- or 4-carboxyethylpyrrol-2-34)-methylidenyl]-indolin-2-ones as inhibitors of VEGF, FGF and PDGF receptor tyrosine kinases. I Med. Chem. (1999) 42:5120–5130.
   PubMed Web of Science ®Google Scholar
• SHAHEEN RM, DAVIS DW, LIU W et al.: Anti-angiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. (1999) 59:5412–5416.
   PubMed Web of Science ®Google Scholar
• ROSEN LS, ROSEN PJ, KABBINAVAR Fet al.: Phase I experience with 5U6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol (2001) 20:383 (Abstract).
   Google Scholar
• KABBINAVAR F, HURWITZ HI, FEHRENBERGER L et al.: Phase II, randomized trial comparing bevacizumab plus fluoruracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Clin. Oncol (2003) 21:60–65.
   Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, CART WRIGHT T et al.: Bevacizumab (a monoclonal antibody to VEGF) prolongs survival in first-line colorectal cancer (CRC): results of a Phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Am. Soc. Clin. Omni (2003) 22:3646 (Abstract).
   Google Scholar
• MENDEL DB, LAIRD AD, SMOLICH BD et al.: Development of 5U5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenic agent. Anti-cancer Drug Des. (2000) 15:29–41.
   PubMedGoogle Scholar
• ELLIS LM, LIU W, FAN F et al.: Synopsis of angiogenesis inhibitors in oncology. Oncology (2002) 16:14–22.
   PubMed Web of Science ®Google Scholar
• TAKAHASI Y, BUCANA CD, LIU W et al.: Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: Role of infiltrating cells. J. Nati Cancer Inst. (1996) 88:1146–1151.
   PubMed Web of Science ®Google Scholar
• SOLDI R, MITOLA S, STRASLY M et al.: Role of a‘133 integrin in the activation of vascular endothelial growth factor receptor-2. Bathe J. (1999) 18:882–892.
   Google Scholar
• MEYER D, NICKOLS G, PEGG J, WESTLIN W: An oral aj33 antagonist, S247, induces tumor regression and inhibits hypercalcemia of malignancy in a syngeneic mouse colon model. Proc. Am. Assoc. Cancer Res. (2001) 42:825–831.
   Google Scholar
• BROOKS PC, MONTGOMERY AM, ROSENFELD M et al.: Integrin avB3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79:1157–1164.
   PubMed Web of Science ®Google Scholar
• KERR JS, VVEXLER RS, MOUSA SA et al.: Novel small molecule cc integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. Anti-Cancer Res. (1999) 19:959–968.
   PubMed Web of Science ®Google Scholar
• O'REILLY MS, HOLMGREN L, SHING Y et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a lewis lung carcinoma model. Cell (1994) 79:315–328.
   Google Scholar
• BOEHM T, FOLKMAN J, BROWDER T et al.: Anti-angiogenic therapy of experimental cancer does not induce drug resistance. Nature (1997) 390:404–407.
   PubMed Web of Science ®Google Scholar
• DONG Z, KUMAR R, YANG X et a/.: Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell (1997) 88:801–810.
   Google Scholar
• CHEN QR, KUMAR D, STASS SA et al:Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. (1999) 59:3308–3312.
   PubMed Web of Science ®Google Scholar
• O'REILLY MS, BOEHM T, SHING Y et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88:277–285.
   Google Scholar
• DKHISSI F, LU H, SORIA C et al.: Endostatin exhibits a direct antitumor effect in addition to its aniangiogenic activity in colon cancer cells. Hum. Gene Ther. (2003) 14:997–1008.
   PubMed Web of Science ®Google Scholar
• DHANABAL M, RAMCHANDRAN R, WATERMAN MJ et al.: Endostatin induces endothelial cell apoptosis. J. Biol. Chem. (1999) 274:11721–11726.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA Y, DHANABAL M, GRIFFOEN AW et al.: Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res. (2000) 60:2190–2196.
   PubMed Web of Science ®Google Scholar
• HANSMA AHG, HOEKMAN K, BROXTERMAN HJ et al.: A Phase I study of rhEndostatin: continous infusion (iv) followed by subcutaneous administration. (2002) Proc. Am. Soc. Clin. Oncol 21:110a.
   Google Scholar
• DICKER AP, BONANNI AR, SIDOR C et al.: Phase I trial results of recombinant human angiostatin protein (rhA) and external beam radiation therapy (EBRT). (2002) Proc. ASCO 21:7a.
   Google Scholar
• EZEKOWITZ RA, MULLIKEN JB, FOLKMAN J et al.: Interferon alfa-2a therapy for life threatening hemangiomas of infancy. N Engl. J. Med. (1992) 326:1456–1463.
   PubMed Web of Science ®Google Scholar
• NOR JE, MITRA RS, SUTORIK MM et al.: Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J. Vasc. Res. (2000) 37:209–218.
   PubMed Web of Science ®Google Scholar
• BROWDER T, BUTTERFIELD CE, KRALING BM et al.: Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. (2000) 60:1878–1886.
   PubMed Web of Science ®Google Scholar
• MANS, BOCCI G, FRANCIA G et al.: Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. (2002) 62:2731–2735.
   PubMed Web of Science ®Google Scholar
• KLEMENT G, BARUCHEL S, RAK J et al.: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. (2000) 105:R15–R24.
   PubMed Web of Science ®Google Scholar
• ELLIS LM, LIU W, AHMAD SA et al.: Role of angiogenesis inhibitors in cancer treatment. Oncology (2001) 15:39–46.
   PubMedGoogle Scholar
• PASQUALINI R, RUOSLAHTI E: Organ targeting M vivo using phage display peptide libraries. Nature (1996) 380:364–366.
   PubMed Web of Science ®Google Scholar